Edition:
United States

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

955.00DKK
4:20am EST
Change (% chg)

kr.-4.00 (-0.42%)
Prev Close
kr.959.00
Open
kr.959.00
Day's High
kr.967.00
Day's Low
kr.955.00
Volume
1,190
Avg. Vol
15,880
52-wk High
kr.1,230.00
52-wk Low
kr.646.00

Latest Key Developments (Source: Significant Developments)

ALK-Abello Q4 EBITDA Falls To DKK 61 Million
Tuesday, 6 Feb 2018 01:30am EST 

Feb 6 (Reuters) - ALK-ABELLO A/S ::ALK RELEASES ITS ANNUAL REPORT 2017.Q4 TOTAL REVENUE DKK ‍763​ MILLION (REUTERS POLL: DKK 771 MILLION).Q4 ‍OPERATING PROFIT (EBITDA) WAS DKK 61 MILLION (96)​." ‍WE EXPECT DOUBLE-DIGIT REVENUE GROWTH FROM 2019 ONWARDS WITH NUMEROUS POTENTIAL UPSIDES"​.‍FULL-YEAR OUTLOOK IS IN LINE WITH PRELIMINARY OUTLOOK PRESENTED ON 4 DECEMBER 2017​.SALES OF LEGACY PRODUCTS WERE AFFECTED AS THE CAPACITY CONSTRAINTS CONTINUED TO LIMIT SALES‍​.  Full Article

ALK-Abello Provides Pricing In New Share Issue
Thursday, 7 Dec 2017 02:01am EST 

Dec 7 (Reuters) - Alk-Abello A/S ALKb.CO::PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.- ON 11 DECEMBER 2017 ALK WILL ISSUE A TOTAL OF 92,076 NEW AA SHARES AND 920,760 NEW B SHARES AT DKK 690 PER SHARE.OFFERING RESULTING IN GROSS PROCEEDS FOR ALK IN THE AMOUNT OF DKK 698,856,840.  Full Article

Alk-Abelló to issue shares in private placement
Wednesday, 6 Dec 2017 11:03am EST 

Dec 6 (Reuters) - ALK-ABELLO A/S ::ALK-ABELLÓ A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT.  Full Article

ALK-Abello To Invest Around DKK 1 Bln In North America​
Monday, 4 Dec 2017 01:39am EST 

Dec 4 (Reuters) - ALK-ABELLO A/S ::‍WILL INVEST APPROXIMATELY DKK 1 BILLION TO SUCCEED IN NORTH AMERICA​.‍2018 REVENUE IS EXPECTED TO BE SLIGHTLY BELOW 2017​.‍AFTER 2018, ALK EXPECTS TO DELIVER ORGANIC REVENUE GROWTH OF 10% OR MORE ANNUALLY​.OVER NEXT FIVE YEARS, ANNUAL TOTAL RESEARCH AND DEVELOPMENT COSTS ARE EXPECTED TO BE IN RANGE OF DKK 400-600 MILLION.SAYS ‍NEW FINANCING IS EXPECTED TO COVER A PROJECTED ACCUMULATED NEGATIVE FREE CASH FLOW OF DKK 1 BILLION​.CONTINUES TO EXPECT FULL-YEAR REVENUE AT AROUND DKK 2.9 BILLION AND OPERATING PROFIT OF DKK 225-250 MILLION.‍OVER NEXT FIVE YEARS, ANNUAL TOTAL RESEARCH AND DEVELOPMENT COSTS ARE EXPECTED TO BE IN RANGE OF DKK 400-600 MILLION​.‍WILL POSITION ITSELF TO PENETRATE NON-AIT MARKET​.  Full Article

Alk-Abello Q3 EBITDA falls to DKK 36 million
Friday, 10 Nov 2017 01:30am EST 

Nov 10 (Reuters) - ALK-ABELLO A/S :Q3 TOTAL REVENUE DKK ‍667​ MILLION VERSUS DKK 630 MILLION YEAR AGO.‍FINANCIAL GUIDANCE FOR FULL-YEAR REVENUE HAS BEEN NARROWED WHILE GUIDANCES FOR OPERATING PROFIT (EBITDA) AND FREE CASH FLOW REMAIN UNCHANGED​.‍FULL-YEAR REVENUE IS NOW PROJECTED AT APPROXIMATELY DKK 2.9 BILLION (PREVIOUSLY DKK 2.8-3.0 BILLION)​.Q3 ‍OPERATING PROFIT (EBITDA) WAS DKK 36 MILLION (110) FOLLOWING PLANNED COST INCREASES TO SUPPORT LONG-TERM GROWTH​.‍2017 OPERATING PROFIT (EBITDA) IS STILL EXPECTED TO BE DKK 225-250 MILLION.​.2017 ‍FREE CASH FLOW IS STILL EXPECTED AT APPROXIMATELY MINUS DKK 700 MILLION.​.REUTERS POLL: Q3 TOTAL REVENUES DKK 677 MILLION, GROUP EBIT LOSS DKK 22.5 MILLION ‍​.  Full Article

ALK-Abello says Jupiter Asset Management reduced ownership in ALK to below 5 pct of share capital​
Thursday, 12 Oct 2017 04:43pm EDT 

Oct 12 (Reuters) - ALK-Abello A/S - :‍Received notification from Jupiter Asset Management, that Jupiter reduced ownership in ALK to below 5% of share capital​.  Full Article

ALK’s partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan
Wednesday, 27 Sep 2017 03:00am EDT 

Sept 27 (Reuters) - ALK-ABELLO A/S ::ALK’S PARTNER, TORII, GAINS APPROVAL FOR JAPANESE CEDAR SLIT-TABLET IN JAPAN .‍ALK'S FINANCIAL GUIDANCE FOR 2017 REMAINS UNCHANGED​.‍CEDARCURE™ IS FIRST SLIT-TABLET TO BE APPROVED FOR BOTH ADULT AND PAEDIATRIC USE IN JAPAN​.‍ALK ENTITLED TO RECEIVE ROYALTIES ON SALES OF CEDARCURE™​.  Full Article

Successful phase III trial for Alk's tree allergy Slit-Tablet
Thursday, 14 Sep 2017 07:15am EDT 

Sept 14 (Reuters) - Alk-abello A/S ::Successful phase III trial for Alk's tree allergy slit-tablet.Alk-Abello A/S - ‍results of trial were highly statistically significant​.Alk-Abello - trial showed that treatment was well-tolerated by patients, with no new or unexpected adverse events reported.Alk-Abello - trial met its primary efficacy endpoint​.  Full Article

ALK to accelerate launches of Odactra in U.S.
Monday, 21 Aug 2017 12:59pm EDT 

Aug 21 (Reuters) - Alk-Abello A/S ::Says ‍FDA transferred U.S. product licences for slit-tablet portfolio to ALK.Says ‍ALK plans to expand pivotal phase III clinical trial on allergic asthma to include U.S. patients based on discussions with FDA​.Says FY guidance for operating profit (EBITDA) revised due to accelerated investments to support earlier launches of HDM-SLIT tablet in USA,CANADA​.Says ‍will bring forward North American launches of house dust mite SLIT-tablet from mid-2018 to Q4 2017​.Says ‍FY EBITDA is now expected to be approximately DKK 225-250 million​.Says ‍full-year revenue is still projected at DKK 2.8-3.0 billion​.Says ‍full year free cash flow is now expected at approximately minus DKK 700 million​.  Full Article

ALK-Abello Q2 EBIT loss at DKK 28 mln, higher than expected
Wednesday, 16 Aug 2017 01:45am EDT 

Aug 16 (Reuters) - ALK-ABELLO A/S :Q2 TOTAL REVENUE DKK ‍691​ MILLION (REUTERS POLL DKK 695 MILLION).‍FINANCIAL GUIDANCE FOR FULL-YEAR REVENUE AND OPERATING PROFIT (EBITDA) IS UNCHANGED.​.‍IS CURRENTLY EVALUATING OPPORTUNITIES TO MOVE FORWARD LAUNCHES OF ACARIZAX FROM 2018 TO 2017​.Q2 EBIT LOSS DKK 28 MILLION (REUTERS POLL LOSS DKK 7.18 MILLION).Q2 NET LOSS DKK 1 MILLION (REUTERS POLL LOSS DKK 3.9 MILLION).  Full Article